US Bancorp
IRLA

US Bancorp’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

US Bancorp’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2
Closed -$6K – 4179
2021
Q4 		$6K Buy
+2
New +$12.2K ﹤0.01% 3599
2021
Q3 		– Hold
0
– – – 3912
2021
Q2 		– Hold
0
– – – 3935
2021
Q1 		– Hold
0
– – – 3819
2020
Q3 		– Hold
0
– -$1K – 3820
2020
Q2 		– Hold
0
– – – 3641

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

US Bancorp's IRLA Position: Q1 2022 in Review

US Bancorp sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2022, closing a stake of 2 shares — an estimated $6K sold.

US Bancorp first reported a position in IRLA in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 85 funds tracked by Wall St. Rank hold IRLA as of Q1 2022.

  • US Bancorp reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • US Bancorp sold 2 IRulya Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $6K.
  • US Bancorp first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • US Bancorp's IRulya Therapeutics Inc. Common Stock position peaked at $6K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2022.

Based on US Bancorp's 13F filing for Q1 2022, filed 11 May 2022.